The COVID-19 pandemic launched a healthcare innovation race without parallel in recent history. Recognizing the need for swift action, companies large and small across the healthcare industry jumped into action to do their part to develop diagnostics, therapeutics, and vaccines for COVID-19. Now that roughly two years have passed since the peak of the pandemic, we have a fuller body of COVID-19-related patenting data from the USPTO and patent offices around the world. While several studies have analyzed COVID-19-related patents — notably, the WIPO 2022 study of COVID-19 vaccines and therapeutics — none have focused specifically on COVID-19 diagnostics patents. 

Will an interview lead to an allowance? Should you appeal? Is it time to abandon? How long is too long between filing and the first office action? As an experienced patent professional, you know that predicting examiner behavior is key to finding the shortest path to an allowance, but without the right data, you’re just guessing.

With the right data, IP practitioners can make nuanced and strategic decisions to aid their patent prosecution process.

Patent analytics drive better prosecution outcomes – including less time to allowance, improved client relationships, and, crucially, increased profitability.

Burnout can lead to an increased risk of error, lower productivity, and increased employee turnover.

Earlier this year, the United States Patent and Trademark Office announced in a Federal Register notice that it is extending its Collaborative Search Pilot program through October 31, 2024.

Administrative tasks are burying you and your firm. The right legal technology can help dig you out.

Having insight into which examiners issue the most OAs can help you decide whether an application is worth pursuing, therefore providing you and your client with the information needed to persist confidently.

From new USPTO offices to landmark Supreme Court patent cases to patent eligibility reform legislation, 2023 has shaped up so far as a busy year for the patent world.

In April 2023, the USPTO announced proposed reforms concerning the PTAB’s discretion to deny petitions for IPR and PGR. The proposed rule would clarify and broaden the PTAB’s discretionary powers.